PharmaNet Demonstrates Commitment to Supporting Public Education Worldwide
The Center for Information and Study on Clinical Research Participation (CISCRP) recognized PharmaNet as this year?s award recipient for ?Supporting the Development of Educational Materials.?
PharmaNet Demonstrates Commitment to Supporting Public Education Worldwide
Boston, MA, June 30, 2008- On Monday June 23, 2008, the Center for Information and Study on Clinical Research Participation (CISCRP) held their 2008 Annual Meeting. Board Chairman, Ken Getz, and President & CEO Diane Simmons, recognized PharmaNet as this year’s award recipient for “Supporting the Development of Educational Materials.” Through their collaboration with CISCRP, a 501(c)(3) nonprofit, PharmaNet made possible the development of country-specific brochures that educate the public about the risks and benefits of volunteering for clinical research studies. Since patient protections and resources are not uniform across the globe, PharmaNet addressed this issue through their support of educational tools that identify government, disease-specific, and industry resources for residents of 12 different nations including: Argentina, Brazil, Canada (French speaking), Czech Republic, France, Germany, Italy, Mexico, Poland, Russia, Spain, and the Ukraine.
Accepting the award on behalf of PharmaNet’s Clinical Recruitment Group was Christine Rhoda, Senior Director, Clinical Research from PharmaNet’s Boston office. According to Ms. Rhoda, “Anybody who is participating in a clinical trial, no matter what part of the world, needs to be adequately informed about participation.” All the attendees at the CISCRP Annual Meeting applauded PharmaNet for helping to address this critical issue.
About PharmaNet - a global, drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. PharmaNet offers clinical-development solutions including consulting services, Phase I clinical studies, bioequivalency and pharmacodynamic studies, bioanalytical analyses, and Phase II, III, and IV clinical development programs. In addition, PharmaNet offers technology tools for managing clinical trial data.
About CISCRP-a non-profit organization located in Dedham, MA that is focused on educating and informing the public about clinical research participation. CISCRP is not involved in recruiting patients for clinical trials nor is it involved in conducting clinical trials.
Contact: Elena Gallagher or Meaghan Dunn, CISCRP
Phone: (781) 326-3400
Fax: (781) 326-3420
Email: [email protected]; [email protected]
Website: www.ciscrp.org
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
